Georgetown Huntington Disease Center Studies New Drug to Control Unwanted Movements
The Huntington Disease Care, Education and Research Center at MedStar Georgetown University Hospital, in collaboration with Georgetown University Medical Center, is studying a new therapy to manage uncontrollable movements, called chorea, experienced by patients with Huntington disease.
June 17, 2014
Explore By Category :
- Blood Management
- Cancer
- Cardiology
- Emergency medicine/trauma
- Endocrinology
- Gastroenterology/digestive diseases
- Healthcare industry
- Innovation
- Interventional Pulmonology
- Interventional Radiology
- Medical Education
- MedStar in the community
- Neurosciences
- Nursing
- Oncology
- Orthopaedics and sports medicine
- Orthopedic
- Pediatrics
- Primary care
- Quality and Patient Safety
- Rehabilitation
- Research
- Stem Cell Transplant and Cellular Immunotherapy
- Technology/IT
- Transplant
- Transplantation
- Women’s services
- Video Gallery
- MedStar Washington Hospital Center News
- MedStar Harbor Hospital News
- MedStar Good Samaritan Hospital News
- MedStar Franklin Square Medical Center News
- MedStar Union Memorial Hospital News
- MedStar Montgomery Medical Center News
- MedStar St. Mary's Hospital News
- MedStar Health System News
- MedStar Southern Maryland Hospital Center News
“First-HD” Study Tests New Huntington Disease Therapy For Tremors
WASHINGTON (June 17, 2014) – The Huntington Disease Care, Education and Research Center at MedStar Georgetown University Hospital, in collaboration with Georgetown University Medical Center, is studying a new therapy to manage uncontrollable movements, called chorea, experienced by patients with Huntington disease.
Huntington disease (HD) is a hereditary, progressively degenerative brain disorder for which there is no cure, and only one approved treatment for symptoms. HD causes involuntary body movements, cognitive decline and a host of behavioral disturbances that slowly diminish a person’s ability to walk, talk and reason.
“First-HD” is a multi-center phase III, randomized study at medical centers in the U.S. and Canada that examines the effectiveness, safety and tolerability of an investigational drug called SD-809. The study is double blind and placebo controlled, meaning neither patients nor doctors know who receives SD-809 or the placebo.
The drug works similarly to the U.S. Food and Drug Administration-approved drug tetrabenazine (Xenazine®), proven to reduce chorea in people with HD. The body metabolizes SD-809 more slowly than tetrabenazine, and researchers want to know if it is effective in controlling chorea, if it can provide more consistent and predictable drug levels and if it can be given less often and at a lower dose than tetrabenazine.
“The potential benefit of this drug is better quality of life,“ said Karen Anderson, M.D., director of the Huntington Disease Care, Education and Research Center, and professor of psychiatry and neurology at MedStar Georgetown. “Often patients who have reached this stage in the disease have trouble swallowing, as well as cognitive issues. It could make life easier for them and their caregivers if they have fewer doses to take and to remember. Controlling the chorea is important to prevent falls and can help a patient maintain a better eating routine, as eating is often disrupted by unwanted body movements.”
Eligible patients are those over the age of 18 with a diagnosis of Huntington disease who have not taken tetrabenazine in the past six months. Participants will be involved in the trial for about four months and will be compensated for study-related travel.
The study is being coordinated by the Huntington Study Group (www.huntington-study-group.org). Funding to Georgetown University for this and other research studies for which Anderson will serve as principal investigator is provided by Auspex Pharmaceuticals.
Media Contact
Marianne Worley
703-558-1287
[email protected]
Patient Contact
To learn more about this and other HD clinical trials, please call Hope Heller at MedStar Georgetown at 202-687-1366.
Category : Innovation , Neurosciences ,
Back to Top
Related News

MedStar Georgetown University Hospital acquires first and only robotic navigation system for spine surgery in Washington, D.C., region
Category : Innovation ,

Study shows Retzius-sparing robotic prostatectomy at MedStar Georgetown University Hospital improves patient quality of life without compromising cancer control
Category : Healthcare industry , Innovation , Oncology ,

New Treatments for Hepatitis-C Open New Possibilities for People Waiting for Kidney Transplant
Category : Innovation , Transplant ,